B001 Angiotensin II — receptor (AT1) blockade reduces ventricular arrhythmias in uncomplicated essential hypertensive patients

P

R

A

S

A

B I - r

A a & F D

(

b

r

u e p w a ( p

P

D

R D P W h

s t

~ @ h

4 w

.Wwto .b.l.

.

S G

.

-

.

m o

m

—.. .

m

s

m

S u a s r d I t f 5 m 5 ( O w s p i f 4 m 4 ( T a r ( O b s b c a p v b d p p and also, less e ( O b b s u a a v b T r s ( O a d ( O correlates w reduction in premature ventricular b i t w I b a m s c w f b r v a a increase s ( c r a v a o d I r b r b p a c s p K

t

b

E

m

* “ ono 5 d @

i

v

s

o

c W C

i

~

d i m f o

i T 4 I ‘ s

A M L .~ ~ m n At h

Q f

Ua h ~ sS E f W sa ~ c

ad

t=n

(d

h a Nm Mu W i S u

cS

&

r

f y

a s n e

O

rf

s

L=

m w t u j h c - c @F i i b an n w s d Oo o l & p l S W I ~ S l W & ~ f t ) m ~ a mMa S o as U h@ ~ a hG s s u us s s ? K a o - l i d‘ bx w bs d s o sm V f s h t a dd o t

P

a

l f as i O A Cw f A t U s i a h c‘ a q s w b es O d m A i a $ k d z a c

i

w l t i s i n a o

d

m

aJ h ? ut s nss f t a ae

r

s $

s

lu

s A ud i l h d Sa t

i l a a on h m if ms s fi @ u & o f e

o r s K

Words

A

W A

Ci

PEa

m

a

a

i f @

k

aW n l

I a

B

B V I L U M U

P A A RAL G NI SO G D DN I Y PS A DS P h F S A L a T M e i Ha y c a p D a D o C e N na p H r&i a od S U eo D n c D D id9 u h u v K i n n i g T a o t s w t e t e tx h 1 a o D6 e l 0c oh s m o o v i o d c nf i E h a ma i d e s rl i s p i uaa r rd a bb t n i j o p c c o l s Mr n aew o t a r d i e o a n Iu( np H a a d gf e r i Rn a t g b e a / k b se o 2 E

T

P

(M

S V

P M

( ( ( ( ( (

m

Em c Am c I F c D

P

c c c

S c v i

w f 1 i

t

n

K

W

O 0 0 0 0

( ( ( ( ( (

p O0 0 0 0 0 0

V ( ( ( ( ( (

R . m

p ( ( ( ( ( (

i

m

. F

o *

=

S

.

, 0 BS SI S ~ . o D M b I M s t s o v ~

m o A

p

m,

!.

1

EFFECTOF ANOIOT’ENSIN n n r COIWERmo ENZYME(ACE) INmBIToRs IN o ACUTEANDCHRONIC M O O O L

ARRHYTHMIAS ,llx,(l !lfxm,,,.\.(Rk:

1

B ~

v

u e h p G D I N R C L EB LC EC AZ R F I M &C S C B I A v a a o e h p e I o f a 4 p m f a y m m a u e h t T E m S w c o a at a t e a I t R

1

a

u

b

a

a B

r d

I

e

e

l a

f u o e

a

m T t

p

w w

ETT RC O E I C G NE A NT NS A N e C ( OC L l T F LE I s I O D m e nr n t y + a e l n+ d s , n iPr n i M s et oP mp w e oe i ng l+ Mt l Mi F n eo S n rc S d o J d Gs D a e il e tl Y G H le U t dC oa m d D M d R U f h aI i uf V a m ih e di c H S S c apg a r sr dp i/ f o dl g a r a a f ne t t als d k a ic o tg ia l i b l e n t i a hl s Ti p td e a ( i bt t n l ci e i (o a u pi ccm s e s g a scr sp ua uoes ehe r l oo p ed b l vm e e yeo r e t r b t A g p t t Ae i en n o s ds a o u c ao r f i so u h u / p l r la 2 m c ls a iw o nt t 2 eg f . e h e c f a p h s ( ! w s a c d ( E I p i I ( ! a m ( T I A g p w d P u t S a w p u R i s f f t d l A g w s a h a c s a f t w n r b ! A g a f o h C L n s a b t A g a h I I ( ( m (1 6 3 3 O a t p w A g s ah p f ( 4 9 2 P c t t I A g p n r e h o p a t e h p w A g s h k I ( t c r w t h p f h s t p AA A T P ~ U i H

I

T a ro

I L

t o

t

a A sIg f x

i

Valsarfan:Angiotensin11,DiastolicDysfunction

r i

ao f K

g h W

l t A p

s

o

a g t

re 1 c

l

lt

n io

e

c

e

g

(

, h

ie i n p v

cn o it e